TP53 somatic mutations are more common in triple-negative [estrogen receptor (ER) negative, progesterone receptor (PR) negative, HER2 negative] breast cancers (TNBC), while PIK3CA mutations are more common in hormone receptor (HR)-positive HER2− tumors. Here, TP53 is linked to breast carcinoma.